Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2

59:16
 
Share
 

Manage episode 503151170 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:

  • Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
  • Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
  • Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn’s disease — Neil Morganstein, MD (17:48)
  • Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
  • Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
  • Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)

CME information and select publications

  continue reading

740 episodes

Artwork
iconShare
 
Manage episode 503151170 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:

  • Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
  • Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
  • Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn’s disease — Neil Morganstein, MD (17:48)
  • Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
  • Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
  • Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)

CME information and select publications

  continue reading

740 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play